Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.49 +0.11 (+0.82%)
Official Closing Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Peering Into Takeda Pharmaceutical's Recent Short Interest
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold... 
Via Benzinga
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome... 
Via Benzinga
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could... 
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Via Benzinga
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
Via Benzinga
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
Via Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which... 
Via Benzinga
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
Upgrades 
Via Benzinga
Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful
Via Benzinga
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
From Takeda Pharmaceutical Company Limited
Via Business Wire
Looking Into Takeda Pharmaceutical's Recent Short Interest
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which... 
Via Benzinga
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. 
Via Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
From Takeda Pharmaceutical Company Limited
Via Business Wire
As Health Problems Mount Patients Welcome New Treatments
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,... 
Via FinancialNewsMedia
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act'
Moderna tested a bivalent booster, which targets two Covid strains in one shot. 
Via Investor's Business Daily
Quant Ratings Updated on 66 Stocks
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10. 
Via InvestorPlace
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Current Report: Takeda Pharmaceutical
Takeda’s price per share was $14.31 as of yesterday's market close. One year ago its price was $17.20. 
Via Talk Markets
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
Via Benzinga
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.